# Fairmount Funds Management LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1802528. Source: https://holderbook.com/funds/1802528-fairmount-funds-management-llc/

- Reported value: $1.5B
- Positions: 12
- Weight of the ten largest: 97.6%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS INC | [ORKA](https://holderbook.com/stocks/ORKA/) | $352.6M | 3,705,262 | 23.3% | 8 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $247.3M | 2,537,191 | 16.3% | 12 |
| DAMORA THERAPEUTICS INC | [DMRA](https://holderbook.com/stocks/DMRA/) | $226.6M | 8,713,000 | 15.0% | 2 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $213.0M | 5,503,418 | 14.1% | 23 |
| JADE BIOSCIENCES INC | [JBIO](https://holderbook.com/stocks/JBIO/) | $101.2M | 4,553,494 | 6.7% | 5 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $94.2M | 1,855,644 | 6.2% | 14 |
| VIRIDIAN THERAPEUTICS INC | [VRDN](https://holderbook.com/stocks/VRDN/) | $93.5M | 5,090,928 | 6.2% | 22 |
| ZENAS BIOPHARMA INC | [ZBIO](https://holderbook.com/stocks/ZBIO/) | $59.9M | 2,359,025 | 4.0% | 8 |
| CRESCENT BIOPHARMA INC. | [CBIO](https://holderbook.com/stocks/CBIO/) | $49.5M | 2,747,866 | 3.3% | 5 |
| APOGEE THERAPEUTICS INC | [APGE](https://holderbook.com/stocks/APGE/) | $39.6M | 298,647 | 2.6% | 12 |
| FAETH THERAPEUTICS INC | [FTH](https://holderbook.com/stocks/FTH/) | $18.1M | 722,020 | 1.2% | 1 |
| INHIBIKASE THERAPEUTICS INC | [IKT](https://holderbook.com/stocks/IKT/) | $17.5M | 8,625,000 | 1.2% | 7 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +32.2% | +14.8% | +17.4% | 100% |
| Q1 2026 | +22.9% | -4.6% | +27.6% | 100% |
| Q4 2025 | +51.6% | +2.4% | +49.3% | 100% |
| Q3 2025 | +28.7% | +7.8% | +20.9% | 100% |
| Q2 2025 | +4.1% | +10.5% | -6.4% | 100% |
| Q1 2025 | -13.4% | -4.6% | -8.9% | 100% |
| Q4 2024 | -18.9% | +2.1% | -21.1% | 100% |
| Q3 2024 | +24.9% | +5.4% | +19.5% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $1.5B | 12 |
| Q1 2026 | $1.4B | 12 |
| Q4 2025 | $1.3B | 13 |
| Q3 2025 | $1.1B | 17 |
| Q2 2025 | $771.9M | 17 |
| Q1 2025 | $644.6M | 15 |
| Q4 2024 | $1.0B | 17 |
| Q3 2024 | $1.2B | 15 |
| Q2 2024 | $885.1M | 13 |
| Q1 2024 | $917.4M | 15 |
| Q4 2023 | $946.5M | 16 |
| Q3 2023 | $831.2M | 20 |